{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T03:35:43Z","timestamp":1792121743780,"version":"4.4.0"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,8,1]],"date-time":"2017-08-01T00:00:00Z","timestamp":1501545600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","lrjournal.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2017,8]]},"DOI":"10.1016\/j.leukres.2017.05.012","type":"journal-article","created":{"date-parts":[[2017,5,13]],"date-time":"2017-05-13T02:15:22Z","timestamp":1494641722000},"page":"26-31","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":28,"special_numbering":"C","title":["Development of a harmonized patient-reported outcome questionnaire to assess myelofibrosis symptoms in clinical trials"],"prefix":"10.1016","volume":"59","author":[{"given":"Chad","family":"Gwaltney","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean","family":"Paty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virginia E.","family":"Kwitkowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruben A.","family":"Mesa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amylou C.","family":"Dueck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elektra J.","family":"Papadopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lixia","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Feliciano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen Joel","family":"Coons","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.leukres.2017.05.012_bib0005","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1056\/NEJMoa051113","article-title":"A gain-of-function mutation of JAK2 in myeloprolifera-tive disorders","volume":"352","author":"Kralovics","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.leukres.2017.05.012_bib0010","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1038\/leu.2010.69","article-title":"Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1","volume":"24","author":"Tefferi","year":"2010","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2017.05.012_bib0015","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.semcdb.2008.07.002","article-title":"Constantinescu SN: JAKs in pathology: role of janus kinases in hematopoietic malignancies and immunodeficiencies","volume":"19","author":"Vainchenker","year":"2008","journal-title":"Semin. Cell Dev. Biol."},{"issue":"August","key":"10.1016\/j.leukres.2017.05.012_bib0020","doi-asserted-by":"crossref","first-page":"e335","DOI":"10.1038\/bcj.2015.63","article-title":"A phase 2 randomized dose-ranging study of the JAK2-selective inhibitor fedratinib (SAR302503) in patients with myelofibrosis","volume":"5","author":"Pardanani","year":"2015","journal-title":"Blood Cancer J."},{"issue":"6","key":"10.1016\/j.leukres.2017.05.012_bib0025","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1038\/leu.2013.71","article-title":"Safety and efficacy of CYT387, a JAK1 and JAK2 inhibitor, in myelofibrosis","volume":"27","author":"Pardanani","year":"2013","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2017.05.012_bib0030","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1182\/blood.V118.21.118.118","article-title":"Results of a phase 2 study of pacritinib (SB 1518), a novel oral JAK2 inhibitor, in patients with primary, post-polycythemia vera, and posy-essential thrombocythemia myelofibrosis","author":"Komrokji","year":"2011","journal-title":"Blood"},{"issue":"21","key":"10.1016\/j.leukres.2017.05.012_bib0035","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1182\/blood.V122.21.664.664","article-title":"BMS-911543, a selective JAK2 inhibitor: a multicenter phase 1\/2a study in myelofibrosis","volume":"122","author":"Roberts","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2017.05.012_bib0040","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.beha.2014.07.010","article-title":"How many JAK inhibitors in myelofibrosis?","volume":"27","author":"Ferreira","year":"2014","journal-title":"Best Pract. Res. Clin. Haematol."},{"key":"10.1016\/j.leukres.2017.05.012_bib0045","doi-asserted-by":"crossref","first-page":"2895","DOI":"10.1182\/blood-2008-07-170449","article-title":"New prognostic scoring system for primary myelofibrosis based on a study of the international working group for myelofibrosis research and treatment","volume":"113","author":"Cervantes","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2017.05.012_bib0050","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.mayocp.2011.11.001","article-title":"One thousand patients with primary myelofibrosis: the mayo clinic experience","volume":"87","author":"Tefferi","year":"2012","journal-title":"Mayo Clin. Proc."},{"key":"10.1016\/j.leukres.2017.05.012_bib0055","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1056\/NEJM200004273421706","article-title":"Myelofibrosis with myeloid metaplasia","volume":"342","author":"Tefferi","year":"2000","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.leukres.2017.05.012_bib0060","first-page":"1","article-title":"Clinical and laboratory features of myelofibrosis and limitations of current therapies","volume":"9","author":"Gregory","year":"2011","journal-title":"Clin. Adv. Hematol. Oncol."},{"key":"10.1016\/j.leukres.2017.05.012_bib0065","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.leukres.2010.07.019","article-title":"MPN-associated myelofibrosis (MPN-MF)","volume":"35","author":"Mesa","year":"2011","journal-title":"Leuk. Res."},{"key":"10.1016\/j.leukres.2017.05.012_bib0070","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1056\/NEJMoa1110557","article-title":"A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis","volume":"366","author":"Verstovsek","year":"2012","journal-title":"New Engl. J. Med."},{"issue":"9","key":"10.1016\/j.leukres.2017.05.012_bib0075","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1016\/j.leukres.2009.01.035","article-title":"The myelofibrosis symptom assessment form (MFSAF): an evidence-based brief inventory to measure quality of life and symptomatic response to treat- ment in myelofibrosis","volume":"33","author":"Mesa","year":"2009","journal-title":"Leuk. Res."},{"key":"10.1016\/j.leukres.2017.05.012_bib0080","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1002\/ajh.24098","article-title":"Myeloproliferative neoplasm patient symptom burden and quality of life: evidence of significant impairment compared to controls","volume":"90","author":"Anderson","year":"2015","journal-title":"Am. J. Hematol."},{"issue":"August","key":"10.1016\/j.leukres.2017.05.012_bib0085","doi-asserted-by":"crossref","first-page":"e335","DOI":"10.1038\/bcj.2015.63","article-title":"A phase 2 randomized dose-ranging study of the JAK2-selective inhibitor fedratinib (SAR302503) in patients with myelofibrosis","volume":"5","author":"Pardanani","year":"2015","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.leukres.2017.05.012_bib0090","series-title":"Paper Presented at the American Society of Hematology Annual Meeting","article-title":"Analysis of outcomes By patient subgroups in patients with myelofibrosis treated with pacritinib vs. best available therapy (BAT) in the Phase III PERSIST-1 trial","author":"Vannucchi","year":"2015"},{"key":"10.1016\/j.leukres.2017.05.012_bib0095","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1038\/clpt.2011.203","article-title":"The Patient-Reported Outcome (PRO) Consortium: filling measurement gaps for PRO endpoints to support labeling claims","volume":"90","author":"Coons","year":"2011","journal-title":"Clin. Pharmacol. Ther."},{"issue":"March (5)","key":"10.1016\/j.leukres.2017.05.012_bib0100","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1002\/(SICI)1097-0142(19990301)85:5<1186::AID-CNCR24>3.0.CO;2-N","article-title":"The rapid assessment of fatigue severity in cancer patients: use of the brief fatigue inventory","volume":"85","author":"Mendoza","year":"1999","journal-title":"Cancer"},{"issue":"April (10)","key":"10.1016\/j.leukres.2017.05.012_bib0105","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1200\/JCO.2012.44.4489","article-title":"Effect of ruxolitinib therapy on myelofibrosis-related symptoms and other patient-reported outcomes in COMFORT-I: a randomized, double-blind, placebo-controlled trial","volume":"31","author":"Mesa","year":"2013","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.leukres.2017.05.012_bib0110","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1182\/blood-2011-01-328955","article-title":"The myeloproliferative neoplasm symptom assessment form (MPN-SAF): international prospective validation and reliability trial in 402 patients","volume":"118","author":"Scherber","year":"2011","journal-title":"Blood"},{"issue":"November (33)","key":"10.1016\/j.leukres.2017.05.012_bib0115","doi-asserted-by":"crossref","first-page":"4098","DOI":"10.1200\/JCO.2012.42.3863","article-title":"Myeloproliferative neoplasm (MPN) symptom assessment form total symptom score: prospective international assessment of an abbreviated symptom burden scoring system among patients with MPNs","volume":"30","author":"Emanuel","year":"2012","journal-title":"J. Clin. Oncol."},{"issue":"6","key":"10.1016\/j.leukres.2017.05.012_bib0120","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1182\/blood-2012-02-414631","article-title":"Long-term outcomes of 107 patients with myelofibrosis receiving JAK1\/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls","volume":"120","author":"Verstovsek","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2017.05.012_bib0125","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.pain.2004.09.012","article-title":"Core outcome measures for chronic pain clinical trials: IMMPACT recommendations","volume":"113","author":"Dworkin","year":"2005","journal-title":"Pain"},{"key":"10.1016\/j.leukres.2017.05.012_bib0130","unstructured":"Food and Drug Administration Guidance for Industry on Qualification Process for Drug Development Tools; Availability. January 7, 2014."},{"key":"10.1016\/j.leukres.2017.05.012_bib0135","doi-asserted-by":"crossref","first-page":"4869","DOI":"10.1002\/cncr.26129","article-title":"Evaluating the serial use of the myelofibrosis symptom assessment form for measuring symptomatic improvement","volume":"117","author":"Mesa","year":"2011","journal-title":"Cancer"},{"key":"10.1016\/j.leukres.2017.05.012_bib0140","series-title":"Poster Presented at the 18th Annual European Meeting of the International Society for Pharmacoeconomics and Outcomes Research","article-title":"Translation and linguistic validation of the modified myeloproliferative neoplasm symptom assessment form: total symptom score (mMPN-SAF TSS) for use in 26 countries","author":"Eremenco","year":"2017"},{"key":"10.1016\/j.leukres.2017.05.012_bib0145","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1136\/bmj.324.7347.1193","article-title":"Patient non-compliance with paper diaries","volume":"324","author":"Stone","year":"2002","journal-title":"Br. Med. J."},{"key":"10.1016\/j.leukres.2017.05.012_bib0150","series-title":"ePRO: Electronic Solutions for Patient-Reported Data","first-page":"127","article-title":"Patient compliance in an ePRO environment: methods for consistent compliance management, measurement and reporting","author":"Shields","year":"2010"}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212617304320?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212617304320?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,10,7]],"date-time":"2020-10-07T14:16:37Z","timestamp":1602080197000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212617304320"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8]]},"references-count":30,"alternative-id":["S0145212617304320"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2017.05.012","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2017,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Development of a harmonized patient-reported outcome questionnaire to assess myelofibrosis symptoms in clinical trials","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.leukres.2017.05.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}